Certara, Inc. delivered a quiet, complicated second quarter that, on the surface, looks like a software company operating in neutral gear. Reported revenue of $93.3M rose only 1% from a year ago, but the real story lives underneath those lines. Software expansion reflects continued demand from existing large pharmaceutical accounts, and the slight services decline reflects the winding down of legacy regulatory work tied to the divested business. The June 2026 quarter is the first full reporting period as a focused software platform after Certara divested its Regulatory and Medical Writing business to Veristat, LLC on May 8, retroactively reclassifying prior periods as discontinued operations and stripping out what was a meaningful services leg of the franchise.
Three structural signals from the quarter stand above the noise. Software gross retention and recurring economics appear intact, with cost of revenue held to roughly 38% of total revenue and operating cash flow from continuing operations producing a positive contribution. The balance sheet remains a fortress, with $184.1M of cash against $295.0M of term loans and a fresh repurchase authorization layered on top of amounts already returned to investors in the first half. A recent Reg FD filing corrected a misstatement around the divested business's 2025 adjusted EBITDA contribution, an atypical optics situation that the company's investor communication needs to address going forward.
The investment debate now turns on whether Certara's software moat can compound at attractive rates as the company laps the divestiture and as model-informed drug development moves further into regulatory and pharma R&D workflows. The stock trades at a discount valuation, with short interest near 26% of float signaling a crowded bear trade that the bull case needs to break. The investment proposition, in short, is a regulatory-grade software platform with a fortress balance sheet, a credible share repurchase tailwind, and a valuation that depends on whether the post-divestiture software growth story re-accelerates over the next several quarters. The thesis is not contingent on blockbuster earnings beats; it depends on consistent execution on the existing roadmap, modest seat expansion within the large-pharma book, and continued adoption of model-informed submissions by mid-sized biotech customers.